Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 capsule plus pegylated interferon alfa-2b and ribavirin for chronic hepatitis C
ACTRN12613001296729Phase 2Completed
- Sponsor
- Biotron Ltd
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hepatitis C (CHC) comparing BIT225 + PEG-IFN + RBV with Placebo + PEG-IFN + RBV (2 arms). Primary endpoint: Safety and tolerability of BIT225 plus pegylated interferon alfa-2b and ribavirin. Started Mar 2014; status: completed.
02
Drugs
BIT225
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on ACTRN12613001296729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001296729.